InsiderClue
Stocks · Health care · Pharmaceutical Preparations

JUPITER NEUROSCIENCES, INC.

JUNS Clue Score19
United States Fiscal year ends December CIK 0001679628
$2.85 +2.89% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $2.85 +77.02% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 3 Dec 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2023Operating income−3.9Net income−4.8EPS, diluted−0.18Fiscal year 2024Revenue0.0Operating income−3.1Net income−2.4EPS, diluted−0.08Fiscal year 2025Revenue0.0Operating income−8.9Net income−8.6EPS, diluted−0.25
FY2023FY2024FY2025
Revenue n/a 0.0 0.0
Growth
Operating income −3.9 −3.1 −8.9
Net income −4.8 −2.4 −8.6
Growth
EPS, diluted −0.18 −0.08 −0.25
Growth

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2023Fiscal year 2024Fiscal year 2025Gross margin80.6%Operating margin−40,873.2%Net margin−39,662.8%
FY2023FY2024FY2025
Gross margin n/a n/a 80.6%
Operating margin n/a n/a −40,873.2%
Net margin n/a n/a −39,662.8%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2023Operating cash flow−0.5Fiscal year 2024Operating cash flow−3.9Fiscal year 2025Operating cash flow−5.4
FY2023FY2024FY2025
Operating cash flow −0.5 −3.9 −5.4

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
FY2023FY2024FY2025
Shareholders’ equity −5.8 4.2 −1.8

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
−0.5 −3.9 −5.4
Growth
Financing
0.4 7.7 5.4

Capital expenditure, dividends and buybacks are shown as money out, so negative.